"10.1371_journal.pone.0072148","plos one","2013-08-28T00:00:00Z","Preciosa M Coloma; Martijn J Schuemie; Gianluca Trifirò; Laura Furlong; Erik van Mulligen; Anna Bauer-Mehren; Paul Avillach; Jan Kors; Ferran Sanz; Jordi Mestres; José Luis Oliveira; Scott Boyer; Ernst Ahlberg Helgee; Mariam Molokhia; Justin Matthews; David Prieto-Merino; Rosa Gini; Ron Herings; Giampiero Mazzaglia; Gino Picelli; Lorenza Scotti; Lars Pedersen; Johan van der Lei; Miriam Sturkenboom; on behalf of the EU-ADR consortium","Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, The Netherlands; Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, University of Messina, Messina, Italy; Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar - Universitat Pompeu Fabra, Barcelona, Spain; Laboratoire dEpidémiologie, de Statistique et dInformatique Médicales (LESIM), LInstitut de Santé Publique, dÉpidémiologie et de Développement (ISPED), University Bordeaux Segalen, Bordeaux, France; Laboratoire dEnseignement et de Recherche sur le Traitement de lInformation Médicale (LERTIM), Faculté de Médecine, Université Aix Marseille 2, Marseille, France; Instituto de Engenharia Electrónica e Telemática de Aveiro (IEETA), Universidade de Aveiro, Aveiro, Portugal; Safety Assessment, AstraZeneca Research and Development, Mölndal, Sweden; Department of Primary Care and Public Health Sciences, Kings College London, London, United Kingdom; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom; Agenzia Regionale di Sanità della Toscana, Florence, Italy; PHARMO Institute, Utrecht, The Netherlands; Società Italiana di Medicina Generale, Florence, Italy; Pedianet-Società Servizi Telematici SRL, Padova, Italy; Department of Statistics, Università di Milano-Bicocca, Milan, Italy; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands","Conceived and designed the experiments: PMC MJS GT MS JvdL. Analyzed the data: PMC MJS GT MS LF AB-M J. Mestres FS EvM PA JK SB EAH RG RH GP GM LS LP JLO. Contributed reagents/materials/analysis tools: PMC MJS MM J. Matthews DP-M RG RH GP GM LS LP MS LF AB-M J. Mestres FS EvM PA JK SB EAH JLO. Wrote the paper: PMC. Oversaw implementation of the database network systems: JvdL. Critically reviewed and approved the manuscript: PMC MJS GT LF EvM AB-M PA JK FS J. Mestres JLO SB EAH MM J. Matthews DP-M RG RH GM GP LS JvdL LP MS.","M. Sturkenboom is running the IPCI research group that occasionally performs studies for pharmaceutical companies (including AstraZeneca, Pfizer, Lilly, Boehringer) and has been consultant to Pfizer, Consumer Health, Novartis, Servier, Celgene, and Lundbeck on issues not related to the study. R. Herings is scientific director of the PHARMO Institute which performs studies for many pharmaceutical companies on issues not related to the study. S. Boyer and E. Helgee are employees of Astra Zeneca. M.J. Schuemie has, since completion of this research, accepted a full-time position at Janssen R&D. G. Mazzaglia has, since completion of this research, started working for the European Medicines Agency (EMA). M. Molokhia has received support from the National Institute for Health Research (NIHR) Biomedical Research Centre at Guys and St Thomas NHS Foundation Trust and Kings College London. None of the other authors have any conflict of interest to declare.","2013","08","Preciosa M Coloma","PMC",25,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
